Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity
Date
2021-05-06
Language
English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Science Direct
Abstract
Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.
Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Hong, G. J., Stinnett, S. S., Freedman, S. F., Wallace, D. K., & Prakalapakorn, S. G. (2021). Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus. https://doi.org/10.1016/j.jaapos.2021.02.002
ISSN
1091-8531
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Journal of American Association for Pediatric Ophthalmology and Strabismus
Rights
IUPUI Open Access Policy
Source
Author
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Author's manuscript